Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.05% $0.200
America/New_York / 6 jul 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 18.24 mill |
EPS: | -0.0700 |
P/E: | -2.86 |
Earnings Date: | May 02, 2023 |
SharesOutstanding: | 91.27 mill |
Avg Daily Volume: | 0.135 mill |
RATING 2023-08-11 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.86 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.49x |
Company: PE -2.86 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.816 - 1.138 ( +/- 16.48%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-04-27 | Robinson James George | Buy | 40 000 | Common Stock |
2023-04-25 | Robinson James George | Buy | 40 000 | Common Stock |
2023-04-25 | Robinson James George | Buy | 40 000 | Common Stock |
2022-05-02 | Robinson James George | Buy | 1 151 515 | Warrant |
2021-04-22 | Robinson James George | Buy | 200 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 1 546 252 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.200 (-0.05% ) |
Volume | 0.882 mill |
Avg. Vol. | 0.135 mill |
% of Avg. Vol | 654.10 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.